You might be hearing a lot about platelet-rich plasma (PRP) in the news these days, with high-profile athletes receiving treatments to not only fix their injuries but also prevent them.
The now-retired Kobe Bryant was a fan years ago, going to Germany for PRP treatments before they were widely available in the US. In a short six years, biologics have gone from Kobe’s age-defying intriguing knee treatment to Lonzo Ball getting a PRP shot and sitting out a month as par for the pro athlete’s course. Angels rookie and Japanese star Shohei Ohtani is currently undergoing PRP treatment in a process he began preventatively last fall, prior to the start of the season. As orthopedic surgeon Dr. David Geier says, “We are entering an age when doctors use biologic treatments such as platelet-rich-plasma (PRP) and stem cells to try to reverse the damage these sports take on the bodies of the athletes…It’s amazing to consider what could be possible going forward.”
The sports world isn’t the only one to embrace the possibilities of PRP. Financial experts also agree that PRP therapy has a solid future ahead, with the market size projected to be about $4.5B by 2024.
Athletes are in. The market says it’s here to stay. What do you say?